Related Experiment Video
Updated: Jul 28, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
Multi-modal cross-attention network for Alzheimer's disease diagnosis with multi-modality data
Jin Zhang1, Xiaohai He1, Yan Liu2
1College of Electronics and Information Engineering, Sichuan University, Chengdu, Sichuan, 610065, China.
Computers in Biology and Medicine
|June 3, 2023
Summary
Accurate Alzheimer's disease (AD) diagnosis is crucial. A new multi-modal cross-attention framework effectively integrates brain imaging and fluid biomarkers, improving diagnostic performance for AD and mild cognitive impairment (MCI).
Area of Science:
- Neuroscience
- Medical Imaging
- Artificial Intelligence
Background:
- Alzheimer's disease (AD) is the leading cause of dementia, making early diagnosis of AD and mild cognitive impairment (MCI) critical.
- Existing deep learning models often concatenate multi-modal data features, overlooking differences in their representation spaces.
- Neuroimaging (sMRI, FDG-PET) and cerebrospinal fluid (CSF) biomarkers offer complementary diagnostic information.
Purpose of the Study:
- To propose a novel Multi-modal Cross-attention AD diagnosis (MCAD) framework for improved AD and MCI detection.
- To effectively learn interactions between different data modalities for enhanced diagnostic accuracy.
- To leverage cross-modal attention to integrate imaging and non-imaging data.
Main Methods:
- Developed an MCAD framework utilizing cascaded dilated convolutions for imaging data and a CSF encoder for non-imaging data.
- Introduced a multi-modal interaction module employing cross-modal attention to fuse sMRI, FDG-PET, and CSF biomarker information.
- Designed an objective function to minimize inter-modal discrepancies and improve feature fusion.
Main Results:
- The MCAD framework achieved superior performance in AD-related classification tasks on the ADNI dataset compared to existing methods.
- Cross-modal attention significantly improved the integration of multi-modal data for diagnostic tasks.
- Analysis confirmed the contribution of each modality and the effectiveness of the cross-attention mechanism.
Conclusions:
- The proposed MCAD framework demonstrates the efficacy of cross-modal attention in integrating diverse biomarkers for accurate AD diagnosis.
- Combining multi-modal data through cross-attention offers a promising approach for early detection of Alzheimer's disease and MCI.
- This method provides a robust tool for enhancing diagnostic performance in neurodegenerative disease research.
Related Concept Videos
Alzheimer's Disease: Overview
536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
Alzheimer's Disease: Treatment
224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224

